Pharmafabrikon Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Pharmafabrikon Pharmaceutical Export Portfolio Dataset — 2 Products, $722.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pharmafabrikon — Pharmaceutical Exporter Profile (2026) | 2 Products, $722.4K Trade | TransData Nexus

Product Portfolio — Top 2 by Export Value

Pharmafabrikon exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Telmisartan	Cardiovascular	$600.0K	12	0.0%	15
2	Clonazepam	CNS & Psychiatric	$122.4K	14	0.1%	8

Pharmafabrikon exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $722.4K. The top category is Cardiovascular (83.1% of portfolio), followed by CNS & Psychiatric (16.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Pharmafabrikon — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Pharmafabrikon, established in 1982, is a partnership firm headquartered in Madurai, Tamil Nadu, India. Founded by a group of pharmacy graduates from Madurai Medical College, the company began with three products under a loan license and has since expanded its portfolio to include a diverse range of pharmaceutical formulations.

Over the past four decades, Pharmafabrikon has grown significantly, now employing a dedicated team of approximately 500 professionals. The company's manufacturing facilities are accredited with WHO-GMP certification, reflecting its commitment to maintaining high-quality standards in pharmaceutical production.

2Manufacturing Facilities

Pharmafabrikon operates two primary manufacturing units in Madurai, Tamil Nadu. Unit I, established in 1987, is situated 7 kilometers from Madurai city in the Othapatti, Karuppayurani area. This facility specializes in the production of beta-lactam category tablets, dry syrups, and capsules, adhering to stringent GMP standards to ensure product quality and safety.

In 2009, the company expanded its operations with the inauguration of Unit II, a 75,000 square-foot facility designed to comply with WHO's cGMP quality norms. This unit focuses on the production of general category dosage forms, including tablets, capsules, and small volume parenterals (SVPs) such as ampoules and vials. The facility's capacity includes the production of 1 billion tablets, 90 million capsules, and 50 million vials and ampoules annually.

3Key Leadership

Pharmafabrikon's leadership team comprises experienced professionals dedicated to steering the company towards continued growth and excellence. Mr. M. Lakshmanan serves as the Managing Director, bringing extensive industry experience to the role. Mr. P. Ponrajan holds the position of President - Marketing, overseeing the company's marketing strategies and initiatives. Mr. A. Gunasekaran serves as the Administrative Director, managing the company's administrative functions. Mr. S. M. D. Kaja Mohideen is the CEO of Orbit Heal Care LLP, a subsidiary of Pharmafabrikon.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Pharmafabrikon Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Pharmafabrikon has made significant strides in expanding its presence in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained WHO-GMP certification, which is a prerequisite for exporting pharmaceutical products to these regions. This certification underscores Pharmafabrikon's commitment to adhering to international quality standards, facilitating market access in these regulated territories.

2Emerging Markets

Pharmafabrikon has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification has enabled it to register products in countries such as Sri Lanka, Myanmar, and the Philippines. Additionally, Pharmafabrikon has gained entry into markets like Singapore and the United Kingdom, reflecting its expanding global footprint.

3Geographic Strategy

Pharmafabrikon's geographic strategy demonstrates a balanced approach between domestic and international markets. While the company has a strong presence in Tamil Nadu and Kerala, it has also made significant inroads into international markets, including Sri Lanka, Myanmar, the Philippines, Singapore, and the United Kingdom. This diversification mitigates concentration risk and positions Pharmafabrikon for sustained growth across various regions.

Pharmafabrikon — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Pharmafabrikon's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), allowing the company to export pharmaceutical products to the United States. The company's adherence to WHO-GMP standards aligns with FDA requirements, facilitating smoother market entry. While specific details regarding approved Abbreviated New Drug Applications (ANDAs) and Drug Master File (DMF) filings are not publicly disclosed, the FDA registration signifies compliance with U.S. regulatory standards.

2WHO & EU GMP

Pharmafabrikon's manufacturing facilities hold WHO-GMP certification, which is recognized by the European Medicines Agency (EMA) and other regulatory bodies. This certification ensures that the company's products meet international quality standards, facilitating access to European markets. The company's commitment to maintaining high-quality manufacturing practices is further evidenced by its compliance with EU GMP guidelines.

3CDSCO & Indian Regulatory

Pharmafabrikon — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Pharmafabrikon operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific market share data is not publicly disclosed, the company's WHO-GMP certification and diverse product portfolio position it favorably in both domestic and international markets. The company's focus on quality manufacturing and ethical marketing practices contributes to its competitive edge.

2Key Differentiators

Pharmafabrikon's key differentiators include its WHO-GMP certified manufacturing facilities, a diverse product portfolio encompassing antibiotics, neuro-psychiatric medications, NSAIDs, respiratory drugs, lifestyle products, and disinfectants, and a dedicated team of approximately 500 professionals. The company's commitment to quality and ethical marketing practices has facilitated effortless acceptance in the medical field.

3Strategic Position

Pharmafabrikon's current strategic direction focuses on expanding its product portfolio and enhancing its manufacturing capabilities to meet both domestic and international demand. The company's adherence to WHO-GMP standards and its commitment to quality manufacturing practices position it well for future growth in the pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Pharmafabrikon as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Pharmafabrikon has demonstrated a consistent track record in pharmaceutical manufacturing, with an annual production capacity that includes 1 billion tablets, 90 million capsules, and 50 million vials and ampoules. The company's adherence to WHO-GMP standards and its commitment to quality manufacturing practices underscore its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Pharmafabrikon as a supplier:

WHO-GMP Certification: This certification ensures that Pharmafabrikon's manufacturing facilities comply with international quality standards. Verification can be obtained by contacting the World Health Organization or the Central Drugs Standard Control Organisation (CDSCO) in India.

EU GMP Certification: This certification indicates compliance with European Union Good Manufacturing Practices. Verification can be obtained by contacting the European Medicines Agency (EMA) or the CDSCO.

Frequently Asked Questions — Pharmafabrikon

How many pharmaceutical products does Pharmafabrikon export from India?

Pharmafabrikon exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Telmisartan ($600.0K), Clonazepam ($122.4K). Total export value is $722.4K.

What is Pharmafabrikon's total pharmaceutical export value?

Pharmafabrikon's total pharmaceutical export value is $722.4K, based on 26 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Pharmafabrikon cover?

Pharmafabrikon exports across 2 therapeutic categories. The largest are Cardiovascular (83.1%, 1 products), CNS & Psychiatric (16.9%, 1 products).

Get Full Pharmafabrikon Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Pharmafabrikon

Pharmafabrikon — Export Portfolio & Destination Treemap

Who is Pharmafabrikon? — Company Overview & Market Position

What Does Pharmafabrikon Export? — Product Portfolio Analysis

Top Products by Export Value

Pharmafabrikon Therapeutic Categories — 2 Specializations